The core innovation is targeted viral vectors. Traditional gene therapy is like broadcasting a message to everyone—Vyriad is building a system that only delivers to the right cells. Their platform combines oncolytic virotherapy with genome editing, creating therapies that attack cancer while sparing healthy tissue. This dual-action approach solves the biggest problem in gene therapy: delivery specificity.

With $5.4M in annual revenue and $33.9M raised, Vyriad is operating at a 6.3x funding-to-revenue ratio—typical for preclinical biotech where the valuation is in IP, not income. The 48% direct traffic rate is unusually high for a biotech startup, suggesting strong brand recognition among investors and partners. The search data reveals telling patterns: 'novartis vyriad' (120 monthly searches) indicates active partnership discussions or legacy relationships, while 'vyriad technology' searches show technical due diligence happening.